About this trial
Restless legs syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs at night when at rest. RLS can lead to a sleep deprivation, increased falling risk, daytime sleepiness, depression and decreased quality of life. Dopamine agonists, alpha-2-delta ligands and opiates are key medications for RLS. The natural course of RLS is very heterogeneous with a risk of increasing the severity of symptoms over the years despite the use of drugs and recommended dosages. Many comorbidities can make RLS worse. Augmentation syndrome is the main complication of dopamine agonists. However, only a few studies have addressed the clinical, biological and pharmacological factors associated with the evolution of the severity of RLS. The objective of this study is to assess the evolution of RLS symptoms severity as function of RLS phenotype, comorbidities and RLS medication, in large cohort of members of the French RLS association and other European RLS association.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults subjects
Restless legs syndrome diagnosis
Member of the restless legs syndrome association
French speaking
Disqualifiers
None
Trial population
Patients with RLS who are members of the RLS patient association
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
International restless legs syndrome study group rating scale (IRLS)
International restless legs syndrome study group rating scale (IRLS). ranging from 0 to 40, with higher scores indicating worse restless legs symptoms
Secondary outcomes
Restless Legs Syndrome-6 Scale (RLS-6)
Restless Legs Syndrome-6 Scale (RLS-6)symptoms after a surgical procedure under general or locoregional anesthesia. ranging from 0 to 60, with higher scores indicating worse restless legs symptoms
Augmentation Severity Rating Scale (ASRS)
Augmentation Severity Rating Scale (ASRS). ranging from 0 to 24, with higher scores indicating worse augmentation symptoms
Epworth severity scale (ESS)
Epworth severity scale (ESS). ranging from 0 to 24, with higher scores indicating worse sleepiness
Insomnia Severity Index (ISI)
Insomnia Severity Index (ISI). ranging from 0 to 28, with higher scores indicating worse insomnia
Sponsors and contacts
Click on the lead sponsor to view all of their trials.